[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340092-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340092-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","durability-of-response-with-selpercatinib-in-patients-with-ret-activated-thyroid-cancer-long-term-safety-and-efficacy-from-libretto-001","Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efﬁcacy From LIBRETTO-001","","Clinical Trial Updates expand access to additional results when co-primary or secondary analyses mature after the initial report. LIBRETTO-001 is a registrational phase I/II single-arm open-label study of selpercatinib for RET (REarranged during Transfection)-activated cancers. At the January 2023 cutoff, objective response rates reached 82.5% in cabozantinib/vandetanib-naive MTC and 95.8% in treatment-naive thyroid cancer. With long follow-up, median progression-free survival was not reached in those groups, and safety remained consistent, supporting durable efficacy with extended follow-up and added patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/durability-of-response-with-selpercatinib-in-patients-with-ret-activated-thyroid-cancer-long-term-safety-and-efficacy-from-libretto-001/340092/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/durability-of-response-with-selpercatinib-in-patients-with-ret-activated-thyroid-cancer-long-term-safety-and-efficacy-from-libretto-001/340092.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of Clinical Trial Updates in this article?","Question",{"text":63,"@type":64},"Clinical Trial Updates disseminate additional study results once key planned co-primary or secondary analyses become available after the initial report.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What study design and population does LIBRETTO-001 evaluate?",{"text":68,"@type":64},"LIBRETTO-001 is a registrational phase I/II, single-arm, open-label study of selpercatinib in patients with RET-activated cancers, including RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"What long-term efficacy outcomes are reported at the January 2023 cutoff?",{"text":72,"@type":64},"Objective response rates were 82.5% for cabozantinib/vandetanib-naive MTC and 95.8% for treatment-naive thyroid cancer, with median progression-free survival not reached in the cabozantinib/vandetanib-naive MTC group and reported at 41.4 months and other group-specific estimates as described.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340092,1790193998,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Clinical Trial Updates  \nDurability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efﬁcacy From LIBRETTO-001  \nLori J. Wirth, MD1 ; Marcia S. Brose, MD2 ; Vivek Subbiah, MD3,4 ; Francis Worden, MD5; Ben Solomon, MD6 ; Bruce Robinson, MD7; Julien Hadoux, MD8 ; Pascale Tomasini, MD9; Daniela Weiler, MD10 ; Barbara Deschler-Baier, MD11; Daniel S.W. Tan, MD12,13  ;  \nPatricia Maeda, MD14 ; Yan Lin, PhD14; Ravinder Singh, PhD14 ; Theresa Bayt, MD14; Alexander Drilon, MD15 ; and Philippe A. Cassier, MD16   \nDOI [https://doi.org/10.1200/JCO.23.02503](https://doi.org/10.1200/JCO.23.02503)  \nABSTRACT  \nClinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.  \nLIBRETTO-001 is a registrational phase I/II, single-arm, open-label study of selpercatinib inpatients with RET (REarranged during Transfection)-activated cancers ([ClinicalTrials.gov](ClinicalTrials.gov)[ ](ClinicalTrials.gov)[identi](identi)ﬁ[er:](er:) NCT03157128). We present long-term safety and efﬁcacy from LIBRETTO-001 inpatients with RET-mutant medullary thyroid cancer (MTC; n 5 324) and RET fusion-positive thyroid cancer encompassing different histological subtypes (TC; n 5 66). At the data cutoff of January 2023, the objective response rate was 82.5% among patients with cabozantinib/ vandetanib-nave MTC and 95 . 8% among patients with treatment-nave TC. At a median follow-up time of 42 .4 and 44 . 0 months in patients with cabozantinib/vandetanib-nave and pretreated MTC, the median progression-free survival (PFS) was not reached and 41.4 months, respectively. At a median follow-up time of 24.9 and 30.4 months in patients with treatmentnave and pretreated TC, the median PFS was not reached and 27 .4 months, respectively. Three-year PFS rates were 75.2% and 87.3% among patients with cabozantinib/vandetanibnave MTC and treatment-nave TC, respectively. Median PFS was similar to median duration of response for each patient group. The safety proﬁle of selpercatinib was consistent with previous reports. With an additional follow-up of 37 months and 228 more patients from the last disclosure, selpercatinib continued to provide durable and robust responses in treatmentnave and previously treated patients with RET-mutant MTC and RET fusion-positive TC.  \nINTRODUCTION  \nSelpercatinib, a ﬁrst-in-class, highly selective, and potent RET  \nMETHODS  \nStudy Design  \nACCOMPANYING CONTENT  \n Data Sharing Statement  \n Data Supplement  Protocol  \nAccepted May 16, 2024  \nPublished August 2, 2024  \nJ Clin Oncol 42:3187-3195 © 2024 by American Society of Clinical Oncology  \nView Online Article  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \n(REarranged during Transfection) inhibitor, is currently approved in several regions around the world, including the United States, European Union, and Japan, for treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusionpositive thyroid cancer(TC)encompassing different histological subtypes in adults and adolescents (age ≥12 years).1-3 These initial approvals were based on the clinical beneﬁts reported in the LIBRETTO-001 trial ([ClinicalTrials.gov](ClinicalTrials.gov) identiﬁer: NCT03157128) in which selpercatinib demonstrated high response rates and favorable toxicity in both treatment-nave and previously treated patients.4 With over 3 years of additional follow-up and more than twice as manypatients, we present the long-term results from safety and efﬁcacy analyses of selpercatinib in patients with RET-activated MTC and TC from the LIBRETTO-001 clinical trial.  \nIn the previously published phase I/II, open-l","cbCaipB0hASHgorP","https://ap.wps.com/l/cbCaipB0hASHgorP","pdf",722797,11,"English","# Abstract\n# Introduction\n# Methods\n## Study Design\n# Efficacy and Safety Measures","[{\"question\":\"What is the purpose of Clinical Trial Updates in this article?\",\"answer\":\"Clinical Trial Updates disseminate additional study results once key planned co-primary or secondary analyses become available after the initial report.\"},{\"question\":\"What study design and population does LIBRETTO-001 evaluate?\",\"answer\":\"LIBRETTO-001 is a registrational phase I/II, single-arm, open-label study of selpercatinib in patients with RET-activated cancers, including RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.\"},{\"question\":\"What long-term efficacy outcomes are reported at the January 2023 cutoff?\",\"answer\":\"Objective response rates were 82.5% for cabozantinib/vandetanib-naive MTC and 95.8% for treatment-naive thyroid cancer, with median progression-free survival not reached in the cabozantinib/vandetanib-naive MTC group and reported at 41.4 months and other group-specific estimates as described.\"}]","Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efﬁcacy From LIBRETTO-001 | PDF",1790034153,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/759d9fc7262bf9819047a6f90e665498.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85b2b2a5f703dab3467fe053da785119.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61e2b703f5912121a38c21d4c3c710f6.webp",981,732,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81bfed479e41d4589a9675047de980d5.webp",980,731]